Veritas In Silico Inc. · TSE:130A
Veritas In Silico — BIO-Europe 2024
19 slides from Veritas In Silico's conference presentation, Nov 4, 2024
Slide 1: Introduction to Veritas In Silico
TYO: 130A Bringing new hope with mRNA-targeted therapies Introduction to Veritas In Silico Ella Morishita, PhD Chief Scientific Officer BIO-Europe 2024
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain forward-looking statements as defined in the United States Private Securities Litigation Reform Act of 1995. The forward-looking statements do not mean that the Company’s management guarantees its future performance. The Company may use expres
Slide 3: Veritas In Silico (VIS) at a glance
Veritas In Silico (VIS) at a glance Japan-based biotech company focusing on mRNA-targeted therapies Founded 2016 Our mission: Deliver Strategic partnerships Pipeline for diseases of IPO 2024 (TSE Growth) life-changing therapies with pharma/biotech unmet medical need • Pioneer in mRNA • Informatics a
Slide 4: A VISionary's journey in mRNA targeting
A VISionary’s journey in mRNA targeting Statistical mechanics + Thermodynamics + Artificial intelligence (AI) = mRNA structural analysis World’s first business model patent CEO and scientific founder for mRNA-targeted small molecule Shingo Nakamura, PhD drug discovery in 2004 ©2024 Veritas In Silico
Slide 5: Our team
Our team World-class scientists with expertise in: Drug discovery mRNA biology Informatics Leadership team with extensive experience in: Pharmaceutical and biotech industries ©2024 Veritas In Silico Inc. 5
Slide 6: Why target mRNA?
Why target mRNA? Targeting mRNA allows us to reach the “undruggable” space and create new therapies “Blueprint of proteins” Disease-related DNA mRNA protein mRNA-targeted Protein-targeted small molecule drugs small molecule drugs, and antisense oligos antibodies, peptides ©2024 Veritas In Silico Inc
Slide 7: ibVIS: mRNA-targeted drug discovery platform
ibVIS: mRNA-targeted drug discovery platform A one-stop solution that integrates informatics and biological tools for mRNA targeting ibVIS platform Target Drug Target identification Screening Hit-to-lead Lead optimization gene candidate mRNA structural Design of 3D Structure Cell-based assays analys
Slide 8: mRNA structural analysis technology
Target Identification Screening Hit-to-lead Lead Optimization mRNA structural analysis technology VIS’ core strength that enables the identification of druggable structures on mRNAs 01 Fast In silico Small molecule target Target structures on mRNA can be identified in significantly less time mRNA st
Slide 9: Scoring system for evaluating mRNA structures
Target Identification Screening Hit-to-lead Lead Optimization Scoring system for evaluating mRNA structures Based on results of over 50 screening programs, constantly updated Structural conservation Thermodynamic Existence stability probability ΔG Location Druggability AUG Total score 10 Current ver
Slide 10: Rigorous validation of candidate mRNA targets
Target Identification Screening Hit-to-lead Lead Optimization Rigorous validation of candidate mRNA targets Conduct tests to check structure and suitability for screening Verify target structure Determine assayability Confirm functionality 120 Absorbance derivative 0.008 ■ Without UPC ■ With UPC RFU
Slide 11: High-throughput screening using qFRET
Target Identification Screening Hit-to-lead Lead Optimization High-throughput screening using qFRET Identifies small molecules that bind to and stabilize mRNA structures mRNA target quantitative FRET (qFRET) (screening probes) Heat F Q F Q F Q F Q F Q A positive change in the melting x temperature (
Slide 12: Stable mRNA structures inhibit protein production
Target Identification Screening Hit-to-lead Lead Optimization Stable mRNA structures inhibit protein production Prevent the formation of the Promote ribosomal collision that signals translation pre-initiation complex peptide or mRNA degradation stalled ribosomes small molecule 43S translation eIF4E
Slide 13: ibVIS screening technology with high success rate
Target Identification Screening Hit-to-lead Lead Optimization ibVIS screening technology with high success rate Obtained small molecule hit compounds for 98% of the 50+ mRNA targets we screened ©2024 Veritas In Silico Inc. 13
Slide 14: Hit compounds show cellular activity
Target Identification Screening Hit-to-lead Lead Optimization Hit compounds show cellular activity In-house With pharmaceutical companies Left: Addition of the compound (VSC0075)—obtained in the screening against a target structure found on the mRNA of a disease-related protein (c- Myc)—to the cells
Slide 15: Techniques to understand binding and identify leads
Target Identification Screening Hit-to-lead Lead Optimization Techniques to understand binding and identify leads Biolayer interferometry (BLI) Isothermal titration calorimetry (ITC) Examine the binding Precisely determine rate between the the binding strength RNA and the of the compounds to compoun
Slide 16: RNA structure determination and quantum mechanics for lead optimization
Target Identification Screening Hit-to-lead Lead Optimization RNA structure determination and quantum mechanics for lead optimization RNA-tailored structure RNA –small molecule Rational optimization of determination technology interaction analysis technology mRNA-targeted small molecules × = ©Yellow
Slide 17: Our pipeline of mRNA-targeted small molecules
Our pipeline of mRNA-targeted small molecules We are developing an in-house pipeline to address diseases of unmet medical need Target identification Screening Hit-to-lead Lead optimization Cancer Lymphoma (gene: c-Myc) Prostate cancer (gene: AR) Various cancers (gene: STAT3) Various cancers Various
Slide 18: Milestone achievements in joint drug discovery
Milestone achievements in joint drug discovery Research with Takeda, Shionogi, RaQualia, and Toray all progressing smoothly PRESS RELEASE in the past year 2024.06.19 Veritas In Silico announces milestone achievement in Takeda collaborative research with Takeda 2024.09.24 Notification regarding achie
Slide 19: Why partner with Veritas In Silico?
Why partner with Veritas In Silico? When you collaborate with us, you gain access to: ibVIS: a cutting-edge Computational and World-class team that mRNA-targeted drug AI capabilities that values collaboration & discovery platform accelerate innovation open communication CONTACT US: contact@veritasin